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Aim: Sarcopenia is deﬁned as the loss of skeletal muscle mass and
strength.It has been correlated with decreased survival but the role of
sarcopenia in penile cancer has not been extensively researched.We
evaluated the association between sarcopenia and mortality rates as well
as therapeutic complications in patients with metastatic penile cancer.
Method: The baseline lumbar skeletal muscle index (SMI¼ Lumbar level 3
Total Muscle Area cm2/height m2) of 38 patients with metastatic penile
cancer was measured on the ﬁrst staging computerized tomography im-
ages performed at the time of diagnosis.Sarcopenia was classiﬁed as an
SMI<55 cm2/m2.
Result: Of 38 patients, 13 (34%) were identiﬁed as having sarcopenia.There
was no signiﬁcant difference in the mean age between patients with and
without sarcopenia (mean 62 vs 60 years).Although the mortality rate was
signiﬁcantly higher in patients with sarcopenia (92% vs 60%), the median
survival did not signiﬁcantly differ (16 vs 17 months).
Conclusion: Mortality is signiﬁcantly higher in patients with metastatic
penile cancer and sarcopenia and further analysis is required to establish
the true prognostic value of sarcopenia in patients with penile cancer.-
However, this preliminary study shows that sarcopenia can be used as a
risk stratiﬁcation tool for patients with metastatic penile cancer.http://dx.doi.org/10.1016/j.ijsu.2016.08.463
0622: UROLOGY REGISTRAR OF THE WEEK: HOW DOES IT IMPROVE PA-
TIENT CARE?
M.M.A. Raza, L. Erete, S. Tadtayev, J. Bycroft T. Lane, D. Hanbury. Lister
Hospital, East & North Hertfordshire NHS Trust, UK.
Aim: To assess the effect of urology registrar of the week (ROW) rota on
patients requiring emergency urology surgery in terms of theatre waiting
times, length of stay (LOS) and readmission rate. The original ROW rota
introduced morning sessions free of elective commitments. The modiﬁed
ROW rota (introduced in January 2015) increased this to both morning and
afternoon sessions.
Method: This completing-the-cycle audit analysed a total of 180 patients
in three monthly periods: pre-ROW, post-original ROWand post-modiﬁed
ROW rota. Retrospective analysis was performed of our emergency theatre
database and inpatient computer system.
Result: There was a total of 73 emergency operations (post-modiﬁed
ROW) compared to 50 (pre-original ROW) and 57 (post-original ROW).
This contributed to a 51% increase in use of emergency theatre. Average
time from admission to theatre booking was reduced by 19%. Theatre
booking to operation time was also reduced from 7 hours (pre-ROW) to
under 5 hours (post-original ROW) and to 3 hours (post-modiﬁed ROW).
LOS and readmission rates (within 30 days) remained comparable.
Conclusion:Despite increasedemergencyprocedures, there isacorrelation in
improved patient care since the introduction of the modiﬁed ROW rota, with
reduced theatre waiting times and comparable LOS and readmission rates.http://dx.doi.org/10.1016/j.ijsu.2016.08.464
0661: LEARNING CURVE IN LAPAROSCOPIC PARTIAL NEPHRECTOMY;
NORTHERN IRELAND SINGLE SURGEON EXPERIENCE
K. Randhawa*, M.R. Evans, W. Elbaroni, J. Keane, A. Thwaini. Belfast City
Hospital, Northern Ireland, UK.
Aim: To evaluate the learning curve for laparoscopic partial nephrectomy
by a single surgeon.
Method: Retrospective review of ﬁrst twenty-four (Group 1) and last
twenty-four (Group 2) laparoscopic partial nephrectomy procedures per-
formed by a single surgeon at one institution. Learning curve was evalu-
ated by examining operative times, warm ischaemia time, estimated blood
loss, postoperative eGFR and postoperative complications.Result: There was a statistically signiﬁcant (p¼0.03) decrease in warm
ischaemia time between initial procedures compared with later proced-
ures; due to larger numbers of later procedures performed with zero
ischaemia time. This did not result in increased EBL peri-operatively (p¼
0.606). Fewer procedures were converted to open in Group 2.
Minimal increase in mean tumour size was observed between the groups
(p¼0.94). There was little difference in nephrometry score; with similar
complexity lesions performed in both groups. Operative time was similar
in both cohorts (p¼0.07).
4% of surgical margins were positive in the ﬁrst cohort compared with 8%
in second cohort. Therewas no difference in eGFR decline between the two
cohorts. Complication rates remained low in both groups.
Conclusion: The learning curve of laparoscopic partial nephrectomy
shows progression of technique towards zero ischaemia time, with no
detrimental effect on oncological outcomes.http://dx.doi.org/10.1016/j.ijsu.2016.08.465
0664: WHAT IS THE INCIDENCE OF UNSUSPECTING INCIDENTAL PROS-
TATE CANCER IN MEN UNDERGOING TRANSURETHRAL RESECTION OF
PROSTATE?
M. Hillen, C. Robinson*, A. Steenkamp, N. Lyons, L. Taylor, P. Bollina.
Western General Hospital, NHS Lothian, Edinburgh, UK.
Aim: Despite a normal prostate speciﬁc antigen (PSA) and digital rectal
exam (DRE), prostate cancer is still diagnosed following a transurethral
resection of prostate (TURP) for suspected benign disease. More men are
undergoing green light laser (GLL) ablation of the prostate without his-
tological assessment, with the potential of missing incidental prostate
cancer cases. We aimed to determine the rate of incidental prostate cancer
in men undergoing a TURP for suspected benign disease.
Method: A retrospective review was performed on all patients who un-
derwent a TURP in 2014 in a single centre. Patient demographics, pre-
operative DRE, PSA and transrectal ultrasound-guided (TRUS) biopsy, and
TURP specimen histology and Gleason Score were recorded.
Result: 169 men without known prostate cancer underwent a TURP in
2014. 24/169 (14.2%) were found to have prostate cancer. 13 of those found
to have prostate cancer had a PSA 5ng/mL.
Conclusion: In our population, the rate of incidental prostate cancer is
7.7%. All men undergoing a TURP should be counselled about the likelihood
of incidental prostate cancer. We are potentially missing a substantial
number of prostate cancer cases in those undergoing GLL and these pa-
tients should have follow-up PSA monitoring or biopsy.http://dx.doi.org/10.1016/j.ijsu.2016.08.466
0685: IS THE REPATRIATION INTO THE COMMUNITY OF MENWITH STA-
BLE PROSTATE CANCER SAFE AND ACCEPTABLE TO PATIENTS AND GEN-
ERAL PRACTITIONERS?
L. Warr 1,*, G. Warren 1, M. Mikhail 3, T. Rashid 2, M. Mikhail 2, M. Winkler 2.
1 Imperial College London School of Medicine, London, UK; 2 Imperial College
Healthcare NHS Trust, London, UK; 3Buckinghamshire Healthcare NHS Trust,
High Wycombe, UK.
Aim: Prostate cancer patients often require life-long PSA surveillance. At
our institution men with with stable prostate cancer are repatriated into
community follow-up.
This study aimed to ascertain patients' experience of their community
management as well as the views of their GPs.
Method: A telephone surveywas conducted to assess patients' satisfaction
levels, complications and preference for community or hospital follow-up.
All patients repatriated between September 2009 and July 2012 were
included. A further survey was sent to the GPs of these patients to assess
their conﬁdence in managing them.
Result: 77 out of 122 repatriated patients completed the survey. Median
follow-up was 100 weeks. 94% were satisﬁed with their follow-up regime.
75% preferred to be followed up by their GP. Therewere no cases of disease
progression attributable to repatriation. 41 GPs ﬁlled out surveys for 59
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agement of such patients.
Conclusion: The repatriation of men with stable prostate cancer is largely
preferred by patients. There is a need for greater patient and GP education
with clear protocols available to give conﬁdence to all parties in follow-up
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.467
0715: VISIBE HAEMATURIA DUE TO UTI e DOES IT NEED
INVESTIGATING?
B. Starmer*, A. Singh, S. Bromage. Stockport NHS Foundation Trust, Stockport,
UK.
Aim: It is well documented that UTI can cause visible haematuria (VH).
Current NICE guidelines suggest that VH secondary to UTI does not need
investigating. While this is intuitive, it is not based on any evidence. We
aim to establish any evidence towards or against this approach.
Method: Retrospective review of casenotes.
Result: There were 599 patients with VH. 299/599 had a negative urinal-
ysis for blood on the day of haematuria clinic. 302/599 had a recorded
MC+S in the 6 weeks prior to ﬂexible cystoscopy. 63/302 patients had a
positive culture on MC+S. 1/63 patient in this group was shown to have a
T1b left renal cell carcinoma. This patient had a positive dipstick on the day
of their haematuria clinic. No bladder tumours were found. 0/29 of those
who had a positive MC+S followed by a negative urinalysis on the day of
haematuria clinic were found to have cancer.
Conclusion: Here, we provide evidence that UTI with VH that has been
treated and has negative urinalysis following this requires no haematuria
investigations. We still advise that persisting non-visible haematuria
following treatment for UTI is investigatedhttp://dx.doi.org/10.1016/j.ijsu.2016.08.468
0793: VENOUS THROMBOEMBOLISM RISK SCORES IN UROLOGICAL PA-
TIENTS: A COMPARISON OF DIFFERENT SCORING METHODS
M. Karia*, S. Onida, A. Davies. Imperial College London, London, UK.
Aim: 1-5% of patients undergoing major urological surgery experience
symptomatic venous thromboembolism (VTE), with pulmonary embolism
(PE) the most common cause of post-operative death. The Caprini and
Department of Health (DoH) scores are assessment systems estimating
VTE risk and the requirement for pharmacological thromboprophylaxis.
The aim of this study was to assess the agreement between these two
assessment methods in urology patients.
Method: 78 patients undergoing urological procedures were prospectively
risk assessed using the Caprini and DoH VTE score and categorized into
low, medium or high risk. Inter-rater agreement was assessed using
Cohen's Kappa coefﬁcient.
Result: There was a 73% agreement between the two scoring methods.
Cohen's kappa coefﬁcient was 0.571 indicating ‘moderate agreement'. Of
the 21 patients where therewas a disagreement, 6 were categorized as low
risk according to one score (3 DoH, 3 Caprini) and medium risk according
to the second score.
Conclusion: We demonstrate a ‘moderate agreement' between scoring
methods in urological patients. The disagreement between low/medium
scoring is clinically relevant, as these patients would have only been pre-
scribed pharmacological thromboprophylaxis depending on the scoring
system used. Further research efforts are required to assess the impact of
differences in these scoring systems in this patient cohort.http://dx.doi.org/10.1016/j.ijsu.2016.08.469
0842: PROSTATIC MEMOKATHS. A LONG-TERM FOLLOW UP OF 35
CASES
C. Mosli-Lynch, N. Chari, L. Forster, C. Tanabalan, P. Patki. St Bartholomew's
Hospital, LONDON, UK.Objective: To examine the long-term efﬁcacy of an expanding metallic
stent (Memokath) placed in patients with obstruction of the prostatic
urethra who were unﬁt or unsuitable for surgical intervention, in order to
determine a population of patients in whom a prostatic memokath would
be a suitable treatment.
Method: We followed up 35 patients who had a prostatic Memokath
placed in a single unit between 2005 and 2009 to assess their long-term
functional outcome. Aside from demographic factors and reason for
insertion we looked at migration rate, replacement rate and survival
times.
Result: Themean age at insertionwas 78.13 patients are still alive with the
Memokath in situ (mean time 86.3 months). 9 patients died with the
Memokath in situ, mean survival time: 29.3months (range 1-69). In eleven
patients the Memokath either migrated (5) or was removed (6) with a
mean time of 3.7 months (range 5 days- 11 months). Two patients were
lost to follow up.
Conclusion: Prostatic Memokaths are useful in patients who are unable to
tolerate either a GA or a LASER resection of the prostate, and who have a
reasonable life expectancy. Though a proportion either migrate or neces-
sitate removal, the majority are well tolerated.http://dx.doi.org/10.1016/j.ijsu.2016.08.470
0930: INITIAL EXPERIENCE OF PROSTATIC URETHRAL LIFT (UROLIFT); A
MINIMALLY INVASIVE TREATMENT FOR SYMPTOMATIC BENIGN PROS-
TATIC HYPERPLASIA
S. Hulligan*, E. Johnson, R. Mistry, H. Gana. Whiston Hospital, Merseyside,
UK.
Introduction: The UroLift procedure in treating LUTS secondary to BPH
has recently been accredited by NICE (September-2015) for men over
50years, with prostates under 100ml without an obstructing middle
lobe. The system avoids the risk to sexual function associated with
current gold standard of TURP, & HoLEP. Initial outcome experience of
Urolift.
Method: Patients assessed both prospectively and retrospectively. Vari-
ables analysed included; pre/post-procedure IPSS, QoL, erectile and ejac-
ulation function. Patients were assessed periodically post-procedure to
evaluate initial outcomes.
Result: 13 Urolift procedures analysed. Mean 65years(range 58-77), all
failed medical management(13). Prostates size 25g-85g, mean PSA 1.66ug/
l. Pre-procedure Qmax mean 13.86ml/sec. All were day-case procedures,
no post-procedure urinary retention, no signiﬁcant adverse effects.
During 1-8months follow up; IPSS mean improved; 20.1(7-31) pre-pro-
cedure to 6.5(1-16) post-procedure(67.7%symptom reduction). QoL score
improved 4.3(2-6)to 1.4(1-6). No QoL improvement in one patient, one
patient 4month delayed improvement due to persistent storage
symptoms.
Post-procedure zero patients experienced retrograde ejaculation. Zero
experienced new erectile dysfunction(ED). 6 had ED prior, zero reporting
deterioration, two reporting improvement.
Conclusion: Urolift is a safe, efﬁcacious treatment of BPH LUTs in the short
term, with a reduction in length of hospital stay. Longer term data will
follow. Preservation of tissue structures ensures sustained sexual function.http://dx.doi.org/10.1016/j.ijsu.2016.08.471
0953: REDUCING THE RISK OF BOWEL INJURY IN OUR NURSE-LED
OUTPATIENT SUPRAPUBIC CATHETER CLINIC
E. Papworth*, R. MacDonagh, A. MacCormick, R. Bamford. Musgrove Park
Hospital, Taunton, UK.
Aim: Rarely, suprapubic catheter insertion is associated with the risk of
bowel perforation. We assessed risk of bowel injury both before and after
the introduction of ultrasound scanning (USS) as an adjunct to SPC
insertion.
Method: A dedicated SPC clinic was established in July 2008, undertaken
by a formally structurally trained specialist nurse.
